Which Zepbound Dose Works Best? 5, 10 and 15 mg Compared in the Trials

Zepbound’s 15 mg dose produces the most weight loss on average, but only by a little over 10 mg. In the 72-week SURMOUNT-1 trial, the average loss among adults without diabetes was 20.9% at the top dose, 19.5% at the middle one and 15.0% at the lowest, with placebo at 3.1%.^[2] The big step is from 5 to 10 mg. The step from 10 to 15 mg adds 1.4 percentage points. Fifteen milligrams once a week is also the highest dose of Zepbound the FDA allows, and the label treats all three maintenance strengths, 5, 10 and 15 mg, as acceptable places to stop.^[1]

Zepbound weight loss by dose: the SURMOUNT-1 numbers

SURMOUNT-1 took 2,539 people without diabetes whose BMI was 30 or more, or 27 or more alongside a condition such as high blood pressure. Each person was randomized to 5, 10 or 15 mg weekly or to placebo, climbed to that dose over up to 20 weeks, and stayed on it to week 72.^[2] Nobody chose their dose, and nobody was moved to a different one. That makes it the cleanest dose comparison tirzepatide has.

These are the figures the FDA label prints.^[1] They use what trialists call the treatment-regimen estimand, which measures everyone who was randomized whether or not they kept injecting.^[2] It answers the question a new patient faces: what happens to people who are prescribed this dose, including those who later stop. Figures from analyses that count only people who kept injecting run higher, so check which one a quoted number comes from. The label also notes that week-72 weights were missing for about one in ten people in each tirzepatide arm and were statistically filled in.^[1]

Is 15 mg Zepbound worth it over 10 mg?

On the average, barely. Moving from 10 to 15 mg added 1.4 percentage points of loss. For someone at the 15 mg group’s starting weight of 105.6 kg, that works out to roughly 1.5 kg, about 3 lb, over a year and a half.^[1] Waist size differed by less than a centimeter.

The top dose earns more of its keep at the far end of the range. The share of people who lost a fifth of their weight rose from 50.1% on 10 mg to 56.7% on 15 mg, a gain of 6.6 points. Compare the step below it: from 5 to 10 mg, that same share rose by 20.1 points, and the average loss by 4.5.^[1]

One caution about reading this table. SURMOUNT-1 was built to compare each dose with placebo, not the doses with one another, and the label prints no statistical test of 15 against 10 mg.^[1] The gap is real in the sense that it was measured in randomized groups. Whether a 1.4-point difference would hold up as significant on its own is not something the trial reports.

With type 2 diabetes, the gap between 10 and 15 mg widens

SURMOUNT-2 tested only the two upper doses, in 938 people who had type 2 diabetes as well as excess weight. At 72 weeks, 10 mg produced a 12.8% loss and 15 mg a 14.7% loss, against 3.2% on placebo.^[3] Both doses lowered HbA1c by the same 2.1 points.^[1]

Here the top dose separates more clearly: 1.9 points on the average, and 9.3 more people in every hundred losing a fifth of their weight. Weight loss was smaller with diabetes at both doses, and in this population the last 5 mg of dose did more work than it did in SURMOUNT-1. For blood sugar alone, the trial found no advantage to going higher.

The same shape after three years

SURMOUNT-1 kept the 1,032 participants who also had prediabetes on their assigned dose for 176 weeks. At three years, their weight was down 12.3% on 5 mg, 18.7% on 10 mg and 19.7% on 15 mg, against 1.3% on placebo.^[4] The pattern from week 72 held: a large step from 5 to 10 mg, then about a point more at 15 mg. Across all three doses, 1.3% of the tirzepatide groups developed type 2 diabetes in that time, against 13.3% on placebo.^[4]

Zepbound side effects by dose

The label pools SURMOUNT-1 and SURMOUNT-2 and reports side effects separately for each dose. Stomach and gut side effects of some kind affected 56% of people on every dose, against 30% on placebo.^[1] What changed with dose was the mix.

• Vomiting climbs with dose. It went from 8% on 5 mg to 13% on 15 mg, and diarrhea from 19% to 23%.^[1]
• Constipation runs the other way. It was most common on 5 mg (17%) and least common on 15 mg (11%).^[1]
• Nausea is flat above 5 mg. 29% on 10 mg and 28% on 15 mg.^[1]
• Stopping because of the stomach rises steadily. 1.9% on 5 mg, 3.3% on 10 mg and 4.3% on 15 mg quit over gut side effects, against 0.5% on placebo.^[1]

Counting every kind of side effect, 4.8%, 6.3% and 6.7% of people on 5, 10 and 15 mg stopped for good, against 3.4% on placebo, most of them in the first few months.^[1] In SURMOUNT-1 alone the order was not tidy: 4.3% on 5 mg, 7.1% on 10 mg and 6.2% on 15 mg.^[2] The gut side effects in that trial clustered in the dose-escalation period.^[2] Pancreatitis, the rare serious risk people ask about, showed no dose pattern: a 2026 meta-analysis of 19 randomized trials put it at 0.22% overall and found no difference between 15 and 10 mg.^[7] The full list of warnings is on the Zepbound side effects page.

Higher doses keep working for longer

A higher dose also stretches the time before weight levels off. In a post hoc analysis of SURMOUNT-1 and SURMOUNT-4, people on 10 or 15 mg were more likely to reach their plateau later. Median time to plateau ran from about 24 to 36 weeks depending on starting BMI, and close to nine in ten had leveled off by week 72.^[5]

A slow start also says little about the finish. In SURMOUNT-1, 18% of people on tirzepatide had lost less than 5% by week 12. By week 72, 90% of those late responders had passed 5%, and higher doses were linked with more people reaching each threshold.^[6] Twelve weeks in, many people are still on the ladder, a point covered in the tirzepatide results timeline.

What is the highest dose of Zepbound?

Fifteen milligrams, injected once a week. The label sets that as the maximum for every indication, weight reduction and obstructive sleep apnea alike.^[1] Doses go up in 2.5 mg steps, with at least four weeks on each, so 15 mg is reachable no sooner than week 21.^[1] No trial of tirzepatide alone above 15 mg has reported results in the medical literature. Any seller offering more than 15 mg a week is offering something outside the approved label.

Every dose from 2.5 to 15 mg comes in each of four forms: a single-dose pen, a single-dose vial, a multi-dose vial and the KwikPen, the last two holding four weekly doses each.^[1] Which strength is which, and how many doses each pen holds, is on the Zepbound KwikPen dose chart; moving between vials and pens is covered by the vial transition calculator.

Who should stay on a lower dose

The label does not rank its maintenance doses. It tells prescribers to weigh “treatment response and tolerability” when choosing one, and to consider a lower maintenance dose for anyone who cannot tolerate theirs.^[1] Only the starting 2.5 mg is ruled out as a long-term dose. For sleep apnea, 5 mg is not a maintenance option; the label requires 10 or 15 mg.^[1]

The SURMOUNT-1 table explains why 5 mg stays on the list. On the lowest maintenance dose, 85.1% of people lost at least 5% and nearly half lost 15% or more.^[1] For someone whose weight is moving and whose stomach is settled, there is no labeled reason to keep climbing. For someone stuck at 5 mg with room to tolerate more, the step to 10 mg is where the trial data show the largest gain. In ordinary care, many people never reach the dose they were meant to try, and a short-term real-world figure for 5 mg is in what a low dose actually does.

Later Zepbound trials dropped the fixed-dose design. The two the label describes after SURMOUNT-1 and -2 let each person settle on 10 mg or 15 mg, whichever was the highest they could tolerate.^[1] SURMOUNT-5, the head-to-head against semaglutide, took the same approach; its result is in the head-to-head and what it settles.

What the dose trials do not settle

• They are group averages. Within every dose arm, some people lost far more than the mean and some far less.
• They assigned doses at random. Real prescribing raises the dose when weight stalls and lowers it when side effects bite, a pattern no fixed-dose trial measures.
• They cover the brand product. Compounded tirzepatide is not the approved drug, and it is not what these trials tested.
• They do not tell you your dose. That depends on your weight trend, your side effects and your other medicines, and it is a decision for your prescriber.

If you buy compounded tirzepatide anyway, the step from 10 to 15 mg may or may not cost you more, depending on the seller. JustAnswer Weight Loss, NiceRx and Precision Telemed charge the same at every dose, and Precision Telemed meets each patient on Zoom before prescribing. RxPros and Alternate Health Club also hold one price across doses, as does MD Total Wellness, a clinic in Brea, California, that dispenses in person from its office. NativeMed keeps its compounded tirzepatide at one monthly price whatever the dose, and so does Trinity Meds, with shipping included.

Others charge by the dose. NP2GO publishes a full list in which each tirzepatide strength has its own price, and Primary Clinic (Direct GLP) prices the drug in dose bands on top of its primary care membership. At sellers like these, the small average gain from the top dose arrives with a larger bill.